Treprostinil (Tyvaso) vs Treprostinil (Yutrepia, Liquidia)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Treprostinil (Tyvaso)
Marketed by United Therapeutics
NCT00147199 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).
Next expected readout: December 2027 · NCT07177703 (registry estimate)
Reported efficacy
Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)
Result source: NCT00147199
Treprostinil (Yutrepia, Liquidia)
Marketed by Liquidia Corporation
NCT03399604 · Phase 3 · completed
The study was an open-label, single-group trial with 121 participants and no placebo or active comparator. Its primary endpoint was treatment-emergent and serious adverse events, rather than a controlled clinical efficacy outcome, so the findings provide limited evidence about the treatment’s comparative effectiveness.
Next expected readout: May 2027 · NCT07759804 (registry estimate)
Reported efficacy
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): LIQ861 Inhaled Treprostinil 121 Participants (not_applicable)
Result source: NCT03399604
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Treprostinil (Tyvaso): 4 of 4 rows · Treprostinil (Yutrepia, Liquidia): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Treprostinil (Tyvaso) | Treprostinil (Yutrepia, Liquidia) |
|---|---|---|
| Dropout rate | 11.3%a NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 11% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result24%LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Discontinued due to AEs | —a NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results— NCT01268553 · Phase 4 · registry result, not featured evidence 4.1% NCT00741819 · Phase 4 · registry result, not featured evidence — NCT00705133 · Phase 2 · registry result, not featured evidence | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Serious AEs | 7.8%a NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 13.7% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence | 12.4%LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Most frequent reported AEs | a cough 53.9% (placebo 29.2%) headache 40.9% (placebo 22.5%) nausea 19.1% (placebo 10.8%) NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 2 more resultsgeneral prostacyclin adverse reaction profile 100% NCT00705133 · Phase 2 · registry result, not featured evidence | cough 33.9% headache 19% upper respiratory tract infection 14.9% NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Treprostinil (Tyvaso)
show 1 more result
show 1 more result
+ 3 further endpoints in the CSV export.
Pulmonary Hypertension Associated with Interstitial Lung Disease
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline
Treprostinil (Tyvaso)
Marketed by United Therapeutics
NCT02630316 · Phase 2/3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 326 people, and inhaled treprostinil significantly improved six-minute walk distance at week 16 compared with placebo (p=0.0043). The trial reported a sample-size calculation for this endpoint and enrolled more participants than the calculation required.
Reported efficacy
Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 (Baseline and Week 16): Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results). (met)
Result source: NCT02630316
Treprostinil (Yutrepia, Liquidia)
Marketed by Liquidia Corporation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Pulmonary Hypertension Associated with Interstitial Lung Disease
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Treprostinil (Yutrepia, Liquidia): no structured comparison results are available for Pulmonary Hypertension Associated with Interstitial Lung Disease.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Treprostinil (Tyvaso)
show 1 more result
Available safety results
Treprostinil (Tyvaso)
| Dropout rate | —Active Inhaled Treprostinil NCT02630316 · Phase 2/3 show 1 more result20.2%Inhaled Treprostinil NCT02630316 · Phase 2/3 |
|---|---|
| Discontinued due to AEs | —Active Inhaled Treprostinil NCT02630316 · Phase 2/3 show 1 more result—Inhaled Treprostinil NCT02630316 · Phase 2/3 |
| Serious AEs | 23.3%Active Inhaled Treprostinil NCT02630316 · Phase 2/3 show 1 more result—Inhaled Treprostinil NCT02630316 · Phase 2/3 |
| Most frequent reported AEs | cough 43.6% (placebo 33.1%) headache 27.6% (placebo 19.6%) dyspnoea 25.2% (placebo 31.3%) NCT02630316 · Phase 2/3 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (Tyvaso)'s landscape · Treprostinil (Yutrepia, Liquidia)'s landscape